Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry
Silverberg J, Gooderham M, Bunick C, Calimlim B, Grada A, Muñoz Maldonado Y, Li A, Fergestrom N, Simpson E. Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s450. DOI: 10.25251/skin.8.supp.450.Peer-Reviewed Original ResearchDermatology Life Quality IndexPP-NRSGlobal Assessment ScaleFollow-up visitAtopic dermatitisQuality of lifeReal-world outcomesSkin clearanceLongitudinal analysisRating ScalePeak Pruritus Numerical Rating ScaleInvestigator Global Assessment scaleSix-month follow-up visitPruritus Numerical Rating ScaleClear/almost clear skinEffect of upadacitinibNon-interventional registryDermatology Life Quality Index scoresNumerical rating scaleAssessment ScaleRegistry of adultsTreating atopic dermatitisEveryday clinical practiceLife Quality IndexImpact of ADTriple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis
Kircik L, Stein Gold L, Gold M, Weiss J, Harper J, Del Rosso J, Bunick C, Bhatia N, Tanghetti E, Eichenfield L, Baldwin H, Draelos Z, Callender V, Han G, Gooderham M, Sadick N, Lupo M, Lain E, Werschler W. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis. Dermatology And Therapy 2024, 14: 1211-1227. PMID: 38724841, PMCID: PMC11116301, DOI: 10.1007/s13555-024-01155-7.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsModerate-to-severe acneClear/almost clear skinTopical acne productsFixed-doseVehicle gelClear skinAcne productsLeast-squares mean percent changesTreatment successEvaluator's Global Severity ScoreIdentical phase 3Acne lesion countsMild-moderate severityGlobal severity scoreReduce antibiotic resistanceNear baseline valuesCutaneous safety/tolerabilityDouble-blindNoninflammatory lesionsResultsAt weekLesion countsAdverse eventsClinical studiesAcne treatmentTriple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis
Stein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s357. DOI: 10.25251/skin.8.supp.357.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsModerate-to-severe acnePhase 3 studyVehicle gelLeast-squares mean percent changesTreatment successEvaluator's Global Severity ScoreClear/almost clear skinIdentical phase 3Inflammatory/noninflammatory lesion countsTopical acne productsMild-moderate severityGlobal severity scoreReduce antibiotic resistanceNear baseline valuesPost hoc analysisCutaneous safety/tolerabilityDouble-blindModerate acneNoninflammatory lesionsClear skinLesion countsAdverse eventsAcne productsSafety resultsTriple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis
Stein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s339. DOI: 10.25251/skin.8.supp.339.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsModerate-to-severe acnePhase 3 studyVehicle gelLeast-squares mean percent changesTreatment successEvaluator's Global Severity ScoreClear/almost clear skinIdentical phase 3Inflammatory/noninflammatory lesion countsTopical acne productsMild-moderate severityGlobal severity scoreReduce antibiotic resistanceNear baseline valuesPost hoc analysisCutaneous safety/tolerabilityDouble-blindModerate acneNoninflammatory lesionsClear skinLesion countsAdverse eventsAcne productsSafety results